Andreea Barbu currently holds a position as senior assessor for biological medicinal products at the Medical Products Agency in Sweden, working with quality assessment and normative activities related to human and veterinary biological products, with special focus on advanced therapies and third generation vaccines. In 2020 she was appointed as one of the Swedish delegates at the Biologics Working Party (BWP), a subgroup on biologics of the CHMP. Since 2017 she is also a member of the Cell Therapy Products Working Party under the European Directorate for the Quality of Medicines (EDQM). Before joining MPA, she has worked several years in academia, latest as Associated Professor in Experimental Endocrinology at Uppsala University. Her primary scientific activities involved evaluation of cell- and gene therapy strategies in the field of diabetes and neuroendocrine tumors, as well as compatibility studies for biomaterials intended for combined cell-based therapies.
AB graduated with a PhD in Medical Cell Biology from Uppsala University, Sweden.